Cochlear Limited delivered underlying net profit of $322 million in FY26, achieving the upper end of revised guidance despite headwinds including flat cochlear implant revenue, lower gross margins, and foreign exchange pressures. Sales revenue increased 2 percent in constant currency to $2.3 billion, though the underlying net profit declined 20 percent in constant currency compared to FY25, reflecting the challenging operating environment and transitional costs.
The divergence between unit growth and revenue performance reveals an important market dynamic. Cochlear implant units increased 5 percent to 56,692, yet revenue remained flat in constant currency, indicating a higher mix of lower-priced emerging market implants offsetting price gains in developed markets. The company achieved an average 3 percent price increase following adoption of the Nucleus Nexa System, its major strategic launch this year, but this was insufficient to overcome the unit mix shift.
The Nexa System represents a significant competitive advantage and a foundation for future growth. As the world’s first smart cochlear implant with upgradeable firmware, it has achieved more than 95 percent of implant sales in developed markets by June, just months after launch. This rapid adoption suggests strong demand and positions Cochlear well to support long-term product differentiation. The system provides a platform for continued innovation without requiring hardware replacement, potentially improving patient lifetime value and loyalty.
Developed market performance provides mixed signals for investors. US cochlear implant revenue grew 4 percent in constant currency, with direct-to-consumer surgeries up 10 percent, indicating traction where Cochlear has direct relationships with referral pathways. However, market growth softened overall, constrained by insurance approval delays and weaker economic conditions. The second half of FY26 showed better momentum, with total sales revenue up 6 percent, suggesting the company navigated the worst of the cyclical pressures.
Cochlear’s FY27 guidance projects low single-digit constant currency sales growth and underlying net profit of $330 million to $350 million, assuming gradual improvement in developed market cochlear implant performance. This implies net profit growth of 2 to 9 percent, predicated on cost discipline and targeted investment in growth initiatives. Investors should monitor the trajectory of developed market implant adoption rates, the sustainability of Nexa System pricing power as competition responds, and whether the company can deliver projected cost reductions while funding growth initiatives. This announcement is price sensitive and has been flagged as material by the ASX.
A rules-based approach to leveraged ETFs
See how our quantitative strategy works and who it suits.
Explore the strategyBecome an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CARView the full ASX announcement (PDF)
About Cochlear Limited (ASX: COH)
Cochlear Limited is the world’s leading manufacturer of cochlear implant devices and other implantable hearing solutions for individuals with severe to profound hearing loss. The company develops and manufactures cochlear implant systems, bone conduction devices, sound processors, and related accessories for children and adults worldwide. Headquartered in Sydney, Australia, Cochlear operates across developed markets in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region.
If you would like to discuss this announcement, request a callback or call us on 1300 889 603.
Learn to trade with a plan
Our free 5-day course covers entries, exits and risk management.
Start the free courseBecome an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CAR